DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY

G. CASINI, G. POLITO, G. BATTISTINI, E. ORLANDI, C. COLLICE, V. CIOFFI, E. M. PROLI
Pharmaceutical Department AOU Policlinico Umberto I - Rome

Atopic dermatitis (AD) is a chronic inflammatory skin disease. It affects 20% of children and 3% of adults. The clinical strategy used in the treatment of moderate and severe forms of AD is the use of Dupilumab in adults and adolescents eligible for systemic therapy. Dupixent is used for the treatment of severe atopic dermatitis with an EASI (Eczema Area and Severity Index) score $\geq 24$, who have an EASI score $\geq 24$; evaluation of pruritus with NRS scale $\geq 7$; quality of life assessment with DLQI index $\geq 10$.

Aim & objectives
The aim of the study was to determine effectiveness and safety of treatment with dupilumab in patients with moderate to severe AD.

Period of study: 01/2020 – 06/2022

A retrospective cohort study was conducted in all patients who began Dupilumab between January 2020 and June 2022 and the data was retrieved from the web-based register of the Italian Medicines Agency. The primary endpoint was the change in the degree of severity of AD assessed by the NRS scale, EASI score, DLQI score and the evaluation of adverse effects to assess safety. The efficacy of dupilumab was established by reduction according to the NRS, EASI and DLQI scale, from the value at the baseline to the value of the last re-evaluation of the disease, carried out after 6 months, and the adverse effects were evaluated during the whole period considered.

Material & methods

Results

<table>
<thead>
<tr>
<th></th>
<th>BEFORE TREATMENT</th>
<th>AFTER TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAN NRS</td>
<td>8,0±2,0</td>
<td>3,2±2,0</td>
</tr>
<tr>
<td>MEAN EASI</td>
<td>26,0±4,0</td>
<td>5,0±4,0</td>
</tr>
<tr>
<td>MEAN DLQI</td>
<td>15,0±7,0</td>
<td>3,0±3,0</td>
</tr>
</tbody>
</table>

Conclusion & relevance
The symptomatic relief of AD led to improved patient’s quality of life, and led quantifiable benefits in the ability to perform daily activities. In agreement with other studies, the use of dupilumab was effective and well tolerated in the management of atopic dermatitis and is an effective alternative for the classical medications.